Levi & Korsinsky notifies investors that it has commenced an investigation into Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) concerning potential violations of the federal securities laws.
Arcturus issued a press release on October 22, 2025, "announc[ing] interim results from its ongoing Phase 2 clinical trial of ARCT-032, an investigational inhaled mRNA therapy for people with cystic fibrosis." The press release disclosed that patients in the trial had not shown a meaningful improvement in forced expiratory volume for one second, or FEV1, a key test for the health of cystic fibrosis patients. Following this news, Arcturus's stock price fell over 50% on October 22, 2025.
If you suffered a loss on your Arcturus Therapeutics Holdings Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





